A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants With Type 1 Diabetes

Carmot Therapeutics

Status and phase: Enrolling; Phase 1

Conditions: Type 1 Diabetes

Treatments: Drug: Victoza; Drug: CT-868; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT05794581

CT-868-005

Details and patient eligibility

About

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

Enrollment: 24 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Female or male adults with Type 1 diabetes
• Ages 18-65 years
• Type 1 DM for at least 3 years
• Using an insulin pump or multiple daily injections (MDI) for at least 3 months
• BMI 25.0 - 35.0

Exclusion criteria

• Significant medical history
• Uncontrolled diabetes
• History of surgical treatment for weight loss
• History of malignancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

24 participants in 3 patient groups, including a placebo group

CT-868

Experimental group

Description:

SC injection of CT-868 Intervention

Treatment:

Drug: CT-868

Placebo

Placebo Comparator group

Description:

SC injection of placebo matching CT-868 dose

Treatment:

Drug: Placebo

Victoza

Active Comparator group

Description:

SC injection of active comparator

Treatment:

Drug: Victoza